US funding for clinical research in South Africa is incrementally being cancelled. This is happening through at least two processes – the first is by banning certain kinds of foreign grants called sub-awards (which is affecting everyone globally). The second is by failing to issue routine renewals of grants for clinical studies in South Africa. Spotlight and GroundUp break down the current situation.
In late-January, the US suspended billions of dollars worth of international aid, including for HIV-related programmes in South Africa. The South African government could have responded by triggering an emergency funding mechanism but has failed to do so yet. In the meantime, activists, health researchers and even technical advisors to government are growing increasingly frustrated with the government’s lack of transparency on this issue.
South Africa’s National Department of Health is still to outline a clear contingency plan as a US funding freeze puts lives at risk, spells job losses, and presents threats to keeping HIV and TB under control. Ufrieda Ho reports.
The National Health Insurance Act does not deal with the systemic issues that cause high prices and inequity in medicine access, and government is not listening, argues Fatima Hassan.
A Competition Commission probe recently resulted in a patent on an important tuberculosis medicine being dropped in South Africa. Twenty years ago, a similar Competition Commission case resulted in a settlement that helped drive down the prices of several antiretrovirals, thereby helping to set the stage for the country’s HIV treatment programme. Fatima Hassan and Leena Menghaney connect the dots between the two landmark cases and map out what has and has not changed over the last two decades.
Between South Africa’s Public Procurement Bill and the National Health Insurance Bill, health sector procurement in the country is set for a major shake-up – all as a landmark court decision recently reaffirmed the Constitutional imperative that public procurement must be conducted in a transparent way. Alicestine October takes a deep dive into the accelerating currents of procurement reform.
Cystic fibrosis (CF) is a debilitating and often deadly disease. Until recently, the only treatments for its symptoms were difficult to administer and time-consuming. Life-changing new treatments that dramatically improve the prognosis for people with the disease have been developed, but they are expensive and Vertex, the US company making the drugs, has decided against registering the drugs in South Africa. Cheri Nel, a woman living with CF, is now taking Vertex on in a South African court. Catherine Tomlinson unpacks the details.
